FortuneNewsWire.com
Info@FortuneNewsWire.com

Global Consortium (OTC:GCGX)

Global Consortium (OTC:GCGX) 

POISED FOR INCREASED GROWTH IN US & CANADIAN MARKET AMID UPDATES ON THE FDA CBD TRIALS

Follow us on TWITTER for more GCGX Updates & Analysis

Conference Call with GCGX (April 4, 2019)

FortuneNewsWire.com 

GLOBAL CONSORTIUM (OTC:GCGX) POISED FOR INCREASED GROWTH IN US & CANADIAN MARKET AMID UPDATES ON THE FDA CBD TRIALS

Top Cannabis companies such as Aphria (NYSE:APHA), Cronos Group (NASDAQ:CRON), Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB) are among the most anticipated cannabis stocks to monitor during these trials, which is set to take place in April to look into how the FDA might legalize CBD-additives in food products. These four cannabis giants stand to benefit significantly from a positive out-come of the trails, which ultimately aim to loosen the constraints of adding cannabis related products to food and drinks.


Now, the FDA is in the middle of it’s first round of public CBD trials, and companies such as Global Consortium Inc. (OTC:GCGX) stand to benefit significantly from the outcome of these trials. This stands particularly true for their extensive line-up of infused edibles, oils, and infusedPETS pet food line. As it stands now, the following is a general description of the current FDA CBD trials. 
1) The FDA will be holding a public hearing on May 31, 2019 to get input from the public in regulating the Hemp CBD;
2) The FDA is creating a “working group” to “explore potential pathways for dietary supplements containing CBD to be lawfully marketed.”
3) The FDA issued three more warning letters to operators whom it believes made medical statements concerning Hemp CBD products that were “egregious”.

Now, GCGX is planning on making its move across the boarder, entering the lucrative capital potential held in Canada. The company went on to explain in a recent press release, “Ongoing discussion are being held to take one of the Company’s divisions public in Canada, where it can receive a higher multiple and gain easier access to capital for expansion. Cannabis companies listed in Canada thrive after going public on the CSE than dual list here is the United States. Opportunities exist all over the United States at reasonable valuations while the country keeps Cannabis in the grey area between State Government and the Federal Government. Utilizing the Canadian markets to raise capital would open up growth potential currently being missed.”

“The Canadian Securities Exchange has seen significant increases in trading, mainy in the cannabis and CBD space. We feel that by listing on the two exchanges the company will attract more investors in both the U.S. and Canada, creating further liquidity and increasing GCGX’s ability to raise capital in a different market.”